标题
Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
作者
关键词
-
出版物
CURRENT CANCER DRUG TARGETS
Volume 23, Issue 6, Pages 433-446
出版商
Bentham Science Publishers Ltd.
发表日期
2023-02-09
DOI
10.2174/1568009623666230209121732
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
- (2022) Alison Cheung et al. International Journal of Environmental Research and Public Health
- Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
- (2022) Hamidreza Ebrahimiyan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
- (2022) Sidrah Shah et al. International Journal of Environmental Research and Public Health
- Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
- (2022) Antonios Revythis et al. International Journal of Environmental Research and Public Health
- BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
- (2022) Stergios Boussios et al. Cancers
- Current Progress of CAR-NK Therapy in Cancer Treatment
- (2022) Zhaojun Pang et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- (2021) Deborah K. Armstrong et al. Journal of the National Comprehensive Cancer Network
- Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
- (2021) Nawid Albinger et al. GENE THERAPY
- The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis
- (2021) Phyllis van der Ploeg et al. GYNECOLOGIC ONCOLOGY
- Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
- (2021) Evangelia Ioannidou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Unraveling the Wide Spectrum of Melanoma Biomarkers
- (2021) Antonios Revythis et al. Diagnostics
- The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
- (2021) Nicholas Pavlidis et al. Cancer Epidemiology
- Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer
- (2020) Bihui Cao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
- (2020) Stergios Boussios et al. Drugs in research & development
- Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
- (2020) Tzu-Ting Huang et al. CANCER TREATMENT REVIEWS
- Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
- (2020) Jason R Brown et al. JCI Insight
- An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
- (2020) Helen Saxby et al. Diagnostics
- Wise Management of Ovarian Cancer: On the Cutting Edge
- (2020) Stergios Boussios et al. Journal of Personalized Medicine
- Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy
- (2020) Xiaoqing Hu et al. BIOMEDICINE & PHARMACOTHERAPY
- Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance
- (2020) Tyler R. McCaw et al. ONCOLOGIST
- NOTCH signalling in ovarian cancer angiogenesis
- (2020) Jose Alejandro Perez-Fidalgo et al. Annals of Translational Medicine
- Metformin and ovarian cancer: the evidence
- (2020) Elina Urpilainen et al. Annals of Translational Medicine
- Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
- (2020) Michele Moschetta et al. Annals of Translational Medicine
- Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
- (2019) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
- (2019) Hye Joung Choi et al. GYNECOLOGIC ONCOLOGY
- MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities
- (2019) San-Nung Chen et al. International Journal of Environmental Research and Public Health
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
- (2019) Xiang Ao et al. JOURNAL OF IMMUNOTHERAPY
- PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
- (2019) Boussios et al. Diagnostics
- Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
- (2019) Isabelle Ray‐Coquard et al. INTERNATIONAL JOURNAL OF CANCER
- Kinase Inhibitors and Ovarian Cancer
- (2019) Katopodis et al. Cancers
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation
- (2018) Guiju Tang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer
- (2018) Debra L. Richardson et al. JAMA Oncology
- A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
- (2018) Stergios Boussios et al. Journal of Advanced Research
- Ovarian carcinosarcoma: Current developments and future perspectives
- (2018) Stergios Boussios et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial
- (2017) Roman Rouzier et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial
- (2017) C. Dinkic et al. GYNECOLOGIC ONCOLOGY
- European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
- (2017) Denis Querleu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Engineering Natural Killer Cells for Cancer Immunotherapy
- (2017) Katayoun Rezvani et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells
- (2017) Benoît Thibault et al. Journal of Ovarian Research
- The role of Notch signalling in ovarian angiogenesis
- (2017) Qi Xie et al. Journal of Ovarian Research
- CAR-T cell therapy in ovarian cancer: from the bench to the bedside
- (2017) Xinxin Zhu et al. Oncotarget
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
- (2016) Weifeng Tang et al. CLINICAL PHARMACOKINETICS
- Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
- (2016) Jie Huang et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer
- (2016) Zhaoyi Feng et al. Oncotarget
- Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
- (2015) F. Kuhnert et al. CANCER RESEARCH
- A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
- (2015) E. G. Chiorean et al. CLINICAL CANCER RESEARCH
- Pazopanib in ovarian cancer
- (2015) Jennifer McLachlan et al. Expert Review of Anticancer Therapy
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Nintedanib: From Discovery to the Clinic
- (2015) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically Relevant microRNAs in Ovarian Cancer
- (2014) Shu Zhang et al. MOLECULAR CANCER RESEARCH
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
- (2014) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- The Role of MicroRNAs in Ovarian Cancer
- (2014) Yasuto Kinose et al. Biomed Research International
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
- (2014) M. Hudecek et al. Cancer Immunology Research
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
- (2013) Zachary Dobbin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
- (2012) Siqing Fu et al. GYNECOLOGIC ONCOLOGY
- Metformin inhibits the development and metastasis of ovarian cancer
- (2012) BUCHU WU et al. ONCOLOGY REPORTS
- Current status and implications of microRNAs in ovarian cancer diagnosis and therapy
- (2012) Mohd Saif Zaman et al. Journal of Ovarian Research
- Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
- (2011) W. Hu et al. CANCER RESEARCH
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response
- (2010) A Hombach et al. GENE THERAPY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
- (2010) P. Hamberg et al. ONCOLOGIST
- Gefitinib
- (2009) Mark Sanford et al. DRUGS
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Notch signaling regulates tumor angiogenesis by diverse mechanisms
- (2008) J Dufraine et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More